Archives: Agenda

• Emerging Industry trends
• Macroeconomic trends
• Technology trends
• Funding trends

• A Smarter, Leaner Approach, Decentralized, and AI-Driven Trials, Built to Cut Complexity and Accelerate Outcomes

Kick things off with the big idea, Milo EDC is built for smarter, faster, and more modern clinical trials.

• The Hidden Costs of Complex eCRF Systems

Highlight how traditional platforms slow things down, cost more, and require specialized roles and training just to function.

• Introduce Milo EDC – Built for the Future

Show how Milo simplifies everything with a unified platform, automation, and patient-first features.

• Market Segments Where Milo Excels

Walk through the key trial types where Milo really shines, from device studies to global CRO deployments.

• Case Study,  Diabetic foot ulcer Trial

Share a real-world example of how Milo helped a sponsor hit enrollment goals early and stay compliant.

• Strategic Advantages for Stakeholders

Break down Milo’s benefits in a quick comparisons: speed, engagement, compliance, and cost.

• Closing & Q&A

Wrap up with a clear message: Milo isn’t just another tool, it’s a strategic enabler for modern trials.

• Fine-tuning the partnership and incentivizing CROs to be more thoughtful in proposals
• How to align financial incentives between data service providers and biotechs so that both sides win
• How will new processes allow for faster data review and ongoing quality assessments to ensure optimal trial outcomes?
• How can we utilize the technology that’s out there and how can it help us move forward in harmonizing siloed teams and organizations

• Endorsing risk-based approaches: Encouraging sponsors to tailor their frameworks to the complexity, scale, and inherent risks of the study to ensure trial data integrity
• Discussing perceived challenges associated with RBQM implementation
• Learn about new comprehensive approaches to assessing RBQM
• Tangible use cases of RBQM adoption and how to meet RBQM standards

• How can sponsors and CROs leverage these updates to enhance the quality and efficiency of clinical trials?
• What are the ways we can pivot our trials to be regulation compliant and what do we need to prioritize?
• How the revised regulation encourages a risk-proportionate approach and a culture of quality that better accommodates ongoing innovation
• What the shift to a RBQM mindset means for the future of clinical data management